In 'Remote Patient Monitoring in Myeloma: How Technology Is Transforming Bispecific Antibody Management,' our panel of experts delve into the following critical question:
In this episode, 'When Transitions Break Down: Real-World Challenges and Lessons Learned in Myeloma Care Handoffs,' the oncology pharmacists explore the following question:
VMAT2 inhibitors show lasting benefit and strong tolerability; dosing, drug interactions, swallowing needs, and liver changes guide switching and long-term use.
Learn how pharmacists use simple talks, handouts and motivational interviewing to start TD therapy early—and choose VMAT2 dosing for adherence.
A member of the cardio-kidney-metabolic syndrome (CKM) guideline writing committee outlines steps pharmacists can take to ensure the kidney component of CKM is not overlooked.
Andrew Li, PharmD, BCOP, discusses key targeted therapy updates in the 2026 ASCO living guideline for stage IV non–small cell lung cancer and how pharmacists can help manage treatment-related toxicities and access barriers.
Boston University researchers say flat chronic kidney disease (CKD) prevalence conceals a growing diabetes-linked burden, and pharmacists have a key role in closing screening gaps.
Beckley Retreats CEO Neil Markey discusses how the recent executive order on psychedelic therapies for veterans could reshape access to ibogaine and other investigational treatments.
This week's episode covers a multistate rise in cyclosporiasis infections, insights from a Yale psychiatrist on safety monitoring for psychedelic therapies, and a wave of FDA approvals spanning nephrology, gene therapy, and cell therapy—plus a major expansion of the NIH's All of Us Research Program.
Pharmacy Times interviews Nicole McMullin, regional clinical pharmacist at American Oncology Network, on patient and caregiver education, home monitoring, multidisciplinary coordination, and key lessons for community oncology practices implementing outpatient BiTE therapy.
Learn how pharmacists secure access to new therapies with copay cards, BlinkRx pricing, and prior-authorization tips that cut delays.
The panelists examined the practical pathways available to community pharmacists who want to build their menopause expertise, with a strong consensus around The Menopause Society as a foundational starting point, offering position statements, continuing education, an annual meeting boot camp, and a certification pathway open to pharmacists, nurse practitioners, physical therapists, mental health counselors, and physicians.
In an interview with Pharmacy Times, Deanna Horner, PharmD, BCPS, discusses how pharmacists can serve as patient advocates in GLP-1 care and how direct access models may simplify the patient journey while preserving clinical oversight.
In this episode, 'BCMA Biology, Mechanisms of Action, and Unmet Needs in Relapsed/Refractory Multiple Myeloma,' the expert oncologists and oncology pharmacists explored the following questions: What is the biological rationale for targeting B-cell maturation antigen (BCMA) in multiple myeloma? What are the different types of BCMA-targeted therapies and what are the Food and Drug Administration (FDA)-approved options? How do the mechanisms of action differ for the 3 different types of BCMA-targeted therapies? What unmet needs in relapsed/refractory multiple myeloma (RRMM) are addressed by BCMA-directed therapies? What are the potential clinical benefits and risks of introducing B-cell maturation antigen (BCMA)-targeted therapies earlier in the treatment continuum?
Welcome back to another Pharmacy Times Practice Pearls series. In this episode titled, 'Rationale and Timing: The Evolving Role of BCMA-Targeted Therapies in Relapsed/Refractory Multiple Myeloma,' Ryan Haumschild led the conversation about the following question: What are the potential clinical benefits and risks of introducing B-cell maturation antigen (BCMA)-targeted therapies earlier in the treatment continuum?
Pharmacy Times interviews Nicole McMullin, regional clinical pharmacist at American Oncology Network, about the oncology pharmacist’s role in outpatient BiTE therapy and the monitoring protocols for identifying and managing CRS and ICANS during step-up dosing.
In an interview with Pharmacy Times, Deanna Horner, PharmD, BCPS, discusses how data, automation, provider-led programs, and pharmacist support can help improve GLP-1 access, appropriate use, adherence, and patient persistence.
This episode, titled 'Roles, Resources, and Relationships: The Stakeholder Framework Behind Successful Myeloma Care Transitions,' features oncology pharmacists discussing the following critical questions:
In 'When It Works: Best-Case Scenarios and Lessons Learned From Successful Care Transitions in Myeloma,' our panel of experts delve into the following critical question:
Pharmacy Times interviews Nicole McMullin, regional clinical pharmacist at American Oncology Network, on how BiTE therapy is changing care for relapsed/refractory multiple myeloma and how AON developed an all-outpatient step-up dosing model.
In addition to the upcoming Annual Forum in September, New England Institute of Ambulatory Care Pharmacists (NEIAP) provides practical education and networking opportunities to support ambulatory care pharmacists.
Wendy St Peter, PharmD, explains how the new cardio-kidney-metabolic (CKM) syndrome guideline supports pharmacist-led medication management, staging tools, and deprescribing.
Katelyn O'Brien, PharmD, BCPS, CDCES, BC-ADM, discusses the New England Institute for Ambulatory Care Pharmacy (NEIAP) Annual Forum and previews key topics of discussion.
The panelists examined the valuable role caregivers can play in identifying early TD movements, noting that patients often mask symptoms during office visits but may not do so around loved ones, and that caregiver education through accessible resources, such as sponsored videos, can help them recognize subtle signs
Tardive dyskinesia disrupts adherence, caregivers, and costs—learn why inpatient and telehealth visits often miss mild symptoms and what to do.
Deanna Horner, PharmD, BCPS, discusses how payers, employers, and health plans can approach GLP-1 coverage by balancing patient access, affordability, clinical value, and long-term cost considerations.
AZA Allsop, MD, PhD, outlines what REMS-style safety monitoring could look like for psychedelic therapies and why top institutions are investing heavily.
Pharmacy Times interviews Tanya J. Uritsky, PharmD, BCPP, FPPCP, FASHP, on how health systems can evaluate suzetrigine for acute pain pathways while balancing evidence, access, formulary sustainability, and pharmacist-led stewardship.
See how a team-based menopause clinic pairs pharmacists, gynecologists, and pelvic floor therapy to streamline care, screening, and symptom relief.
Learn how pharmacists open symptom-first menopause talks, weigh hormonal vs nonhormonal options, and counter social media myths.
